Recombinant Human GALNT1 Protein，GST

GALNT1 (Polypeptide N-Acetylgalactosaminyltransferase 1) is an enzyme involved in the post-translational modification of proteins through O-glycosylation, specifically by adding N-acetylgalactosamine (GalNAc) to serine or threonine residues on target proteins. This modification plays a crucial role in various biological processes, including cell signaling, adhesion, and immune responses. Recent studies have highlighted the importance of GALNT1 in developmental biology and its implications in diseases, such as cancer and congenital disorders. Aberrant glycosylation patterns associated with GALNT1 dysregulation have been linked to tumor progression and metastasis, making it a potential biomarker for cancer diagnostics and therapy. The recombinant production of GALNT1 is fundamental for understanding its enzymatic mechanisms and functional roles in glycosylation. Researchers aim to elucidate the structure-function relationship of GALNT1 through overexpression in suitable host systems, enabling the investigation of its activity, stability, and interactions with substrate proteins. Additionally, characterizing GALNT1 in a recombinant format provides a platform for high-throughput screening of small molecules or inhibitors that can modulate its activity, offering insights into therapeutic avenues for diseases related to glycosylation anomalies. Ultimately, the study of GALNT1 through recombinant protein research holds promise for advancing our knowledge of glycosylation and its impact on health and disease.